Waters BioAccord System with ACQUITY Premier Brings Greater Simplicity, Accuracy and Reproducibility to Multi-Attribute Monitoring of Biopharmaceuticals
September 15 2021 - 9:00PM
Business Wire
News Summary:
- New LC-MS system delivers accurate and reproducible results for
multi-attribute monitoring of biologics.
- Eliminates analyte-to-metal surface interactions greatly
enhancing recovery of hard-to-detect sample analytes.
- Gives more scientists greater access to MS data to improve
quality, reduce costs, and ultimately help get medicines to
patients faster.
Waters Corporation (NYSE:WAT) today introduced the Waters™
BioAccord™ System with ACQUITY™ Premier, a combination of the
Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™
with MaxPeak™ High Performance Surface (HPS) technology. The
integrated high-resolution LC-MS system simplifies multi-attribute
monitoring of biotherapeutics by improving analyte recovery and
assay-to-assay reproducibility so that regulated laboratories can
get needed medicines to patients faster.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210915005862/en/
The Waters BioAccord System with ACQUITY
Premier is an easy-to-deploy and operate LC-MS system for
performing multi-attribute monitoring of biotherapeutics and gives
more scientists access to mass spectrometrty data. It can greatly
improve analyte recovery and assay-to-assay reproducibility so that
companies can improve process and product quality, reduce costs and
get needed medicines to patients faster. (Photo: Business Wire)
“As promising as next-generation biotherapeutics are, they can
be difficult to characterize when they contain low-level analytes
which strongly interact and bind to the internal metal surfaces of
conventional LCs, making them almost impossible to detect,” said
Dr. Udit Batra, CEO and President, Waters Corporation. “When it
comes to analyzing biologics, information is currency and by
solving the problem of analyte-to-metal interactions, the BioAccord
System with ACQUITY Premier gives scientists a faster means of
getting information about everything in their samples from the very
first injection.”
The compact, benchtop BioAccord System with ACQUITY Premier
features MaxPeak HPS technology and the SmartMS™-enabled ACQUITY
RDa™ mass detector allowing analysts of all abilities to monitor
critical quality attributes of biotherapeutics and assess the
processes that make them, all while decreasing risk, thanks to
compliant-ready acquisition and data workflows that deliver
consistent data quality from user-to-user and system-to-system.
MaxPeak HPS technology is a hybrid organic/inorganic surface
technology that forms a barrier between the sample and the
biocompatible metal surfaces of both the UPLC inlet and column. By
mitigating, or eliminating altogether, non-specific adsorption,
MaxPeak HPS offers many benefits, among them:
- up to a 300% increase in detector sensitivity for more accurate
glycan profiling, important for monitoring process and product
quality of biologics[1]
- greatly improved analyte recovery and assay sensitivity for the
measurement of modified peptides and impurities that are
undetectable by conventional means
- sharper peak shapes and greater peak capacity for more accurate
analyte identification and data interpretation
- greater reproducibility for separations prone to adsorptive
losses meaning less re-work or troubleshooting, and more confidence
in results
- eliminates need for system passivation that wastes valuable
sample material or ties up instrument cycles
- eases the transfer of methods from site-to-site and from
company-to-company
With automated set-up and guided workflows made possible with
SmartMS technology, the BioAccord System with ACQUITY Premier is
designed for easy deployment. Rapid system startup is enabled
through the delivery of system and applications training with
pre-defined biopharmaceutical methods for each key workflow. And,
because regulatory compliance and data integrity is vital to many
biopharmaceutical laboratories, the system is built on the
waters_connect™ informatics platform backed by an industry-leading
compliant informatics architecture and the worldwide availability
of professional qualification services.
Customer shipments of the BioAccord System with ACQUITY Premier
are expected to begin at the end of this month.
Additional Resources
- Learn more about the BioAccord System with ACQUITY Premier
- Read the blog post: BioAccord System with
ACQUITY Premier: Some things just work better together.
- Connect with Waters via LinkedIn, Twitter, and Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), the world's leading specialty
measurement company, has pioneered chromatography, mass
spectrometry, and thermal analysis innovations serving the life,
materials, and food sciences for more than 60 years. With more than
7,400 employees worldwide, Waters operates directly in 35
countries, including 14 manufacturing facilities, and with products
available in more than 100 countries.
Waters, BioAccord, ACQUITY, SmartMS, RDa, UPLC, waters_connect
and MaxPeak are trademarks of Waters Corporation.
1Typical results based on Waters lab tests of multiple compounds
using both standard UPLC systems and columns compared with ACQUITY
PREMIER system and columns featuring MaxPeak HPS. 300% increase in
detector sensitivity of structurally similar phosphorylated
mannose-6-glycans. Detection sensitivity may vary depending on the
analytes being measured.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210915005862/en/
Brian J. Murphy PR Manager, Corporate Communications Waters
Corporation brian_j_murphy@waters.com +1 508-482-2614
Waters (NYSE:WAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Waters (NYSE:WAT)
Historical Stock Chart
From Sep 2023 to Sep 2024